These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 21771280)

  • 1. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature.
    Azzouni F; Abu samra K
    J Sex Med; 2011 Oct; 8(10):2894-903. PubMed ID: 21771280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-arteritic anterior ischemic optic neuropathy associated with erectile dysfunction medications].
    Krashin-Bichler I; Dotan G
    Harefuah; 2013 Feb; 152(2):84-7, 123. PubMed ID: 23513498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors?
    Aliferis K; Petropoulos IK; Farpour B; Matter MA; Safran AB
    Ophthalmologica; 2012; 227(2):85-9. PubMed ID: 22156704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.
    Laties A; Sharlip I
    J Sex Med; 2006 Jan; 3(1):12-27. PubMed ID: 16409214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
    Lowe G; Costabile RA
    J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil-associated consecutive nonarteritic anterior ischaemic optic neuropathy, cilioretinal artery occlusion, and central retinal vein occlusion in a haemodialysis patient.
    Gedik S; Yilmaz G; Akova YA
    Eye (Lond); 2007 Jan; 21(1):129-30. PubMed ID: 16732206
    [No Abstract]   [Full Text] [Related]  

  • 9. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)].
    Calvet C; Martin K; Robert G; Moore N; Eftekhari P; Farghal H; Molimard M; Ballanger P
    Prog Urol; 2007 Sep; 17(5):920-7. PubMed ID: 17969789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optic atrophy after sildenafil use.
    Sowka JW; Neiberg MN; Vollmer LA
    Optometry; 2007 Mar; 78(3):122-8. PubMed ID: 17321461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil-associated vascular CASUALTIES.
    Oguz H
    Eye (Lond); 2007 May; 21(5):676-7; author reply 677-8. PubMed ID: 17187028
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
    El-Domyati MM; El-Fakahany HM; Morad KE
    Andrologia; 2009 Oct; 41(5):319-21. PubMed ID: 19737280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent uveitis due to sildenafil usage in a patient with Behçet's disease.
    Işık M; Kılıç L; Doğan I
    Rheumatol Int; 2013 Mar; 33(3):803. PubMed ID: 22095394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: association of combined nonarteritic anterior ischemic optic neuropathy (NAION) and obstruction of cilioretinal artery with overdose of Viagra.
    Akash R; Hrishikesh D; Amith P; Sabah S
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):315-7. PubMed ID: 16117695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
    Kamenov ZA
    J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
    Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
    J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy.
    Pomeranz HD; Smith KH; Hart WM; Egan RA
    Ophthalmology; 2002 Mar; 109(3):584-7. PubMed ID: 11874765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.